TARS Tarsus Pharmaceuticals, Inc.

QT62

Latest market price

74.85

+0.65+0.88%

Overview Short InterestFilings

TARSQT62Tarsus Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

74.85+0.88%

Earnings

Up 0.9% — Earnings due 2026-11-03 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

VKTX+1.56%$27.28 ACAD-0.82%$20.59 AMLX+0.63%$28.86 XENE-0.35%$37.41 CELC-0.25%$69.13 ELVN-1.84%$44.25 TNGX+0.84%$22.72 IOVA-11.30%$8.48

Snapshot

Index	—	P/E	—	EPS (ttm)	-1.09	Insider Own	4.35%	Shs Outstand	46.79M	Perf Week	9.75%

Market Cap	3.50B	Forward P/E	73.62	EPS next Y	1.02	Insider Trans	-5.03%	Shs Float	46.65M	Perf Month	-0.81%

Enterprise Value	3.14B	PEG	—	EPS next Q	-1.49			Short Float	12.29%	Perf Quarter	22.06%

Income	-47.00M	P/S	5.77	EPS this Y	—			Short Ratio	6.90	Perf Half Y	17.65%

Sales	607.00M	P/B	10.09	EPS next Y	—	ROA	-7.60%	Short Interest	5.73M	Perf YTD	-8.59%

Book/sh	7.42	P/C	7.78	EPS next 5Y	—	ROE	-13.53%	52W High	91.53 -18.22%	Perf Year	10.86%

Cash/sh	9.62	P/FCF	56.49	EPS past 3/5Y	—	ROIC	-11.15%	52W Low	53.89 38.89%	Perf 3Y	465.33%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	158.86% —	Gross Margin	90.59%	Volatility	3.61% 4.29%	Perf 5Y	172.58%

Dividend TTM	—	EV/Sales	5.18	EPS Y/Y TTM	—	Oper. Margin	-8.00%	ATR (14)	3.12	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	3.17	Sales Y/Y TTM	105.76%	Profit Margin	-7.67%	RSI (14)	55.11	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	3.20	EPS Q/Q	10.42%	SMA20	4.15%	Beta	0.34	Target Price	103.00

Payout	0.00%	Debt/Eq	0.26	Sales Q/Q	68.93%	SMA50	-0.41%	Rel Volume	0.70	Prev Close	74.20

Employees	370	LT Debt/Eq	0.26	Earnings	Nov 03	SMA200	10.43%	Avg Volume	834.82K	Price	74.85

IPO Date	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-124.23% 2.51%	Net Debt/EBITDA	—	Volume	586,519	Change	0.88%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-24-26	Resumed	Goldman Sachs	Buy	$68 → $116
Sep-16-26	Reiterated	Barclays	Overweight	$100 → $110
Sep-08-26	Reiterated	Jefferies	Buy	$58 → $105
Aug-12-26	Reiterated	Oppenheimer	Outperform	$72 → $100
Jul-31-26	Reiterated	Mizuho	Outperform	$100 → $98
Jul-21-26	Reiterated	Guggenheim	Buy	$84 → $89
Feb-05-26	Reiterated	Goldman Sachs	Neutral	$51 → $68
Dec-08-25	Initiated	Barclays	Overweight	$62 → $100
Nov-20-25	Initiated	Mizuho	Outperform	$100
Nov-06-25	Reiterated	Goldman Sachs	Neutral	$45 → $51

Latest News· Times ET

Today

Today07:29AM

My 'Eye' Is On Tarsus Pharmaceuticalsseekingalpha.com

Oct-29-26

Oct-29-2604:30PM

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026globenewswire.com

Oct-28-26

Oct-28-2609:00AM

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthYahoo

08:30AM

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officerglobenewswire.com

Oct-27-26

Oct-27-2611:06AM

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Declinezacks.com

Oct-15-26

Oct-15-2608:41AM

Lisata adds biopharma finance veteran Jeffrey Farrow to boardYahoo

Oct-13-26

Oct-13-2601:06PM

Tarsus Pharmaceuticals Files Prospectus Related To The Proposed Offer And Resale Of Up To 2.91M Shares Of Common Stock By Selling StockholdersBenzinga

Oct-06-26

Oct-06-2608:55AM

Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Optionsseekingalpha.com

Sep-29-26

Sep-29-2608:30AM

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meetingglobenewswire.com

Sep-24-26

Sep-24-2604:04AM

Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price TargetBenzinga

Sep-21-26

Sep-21-2602:16AM

Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysisdefenseworld.net

Sep-18-26

Sep-18-2612:56PM

When To Dump Stocks: These IBD 50 Components Hit Sell SignalsYahoo

Sep-16-26

Sep-16-2604:56AM

Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price TargetBenzinga

Sep-08-26

Sep-08-2610:50AM

Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105Benzinga

Sep-04-26

Sep-04-2608:38AM

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Careglobenewswire.com

Company

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	607	451	183	17	—	—	—	—	—
Cost of Goods Sold Incl. D&A	57	31	13	2	—	—	—	—	—
Gross Profit	550	421	170	16	—	—	—	—	—
Selling, General and Administrative Excl. Other	527	427	237	109	—	—	—	—	—
Research and Development	87	64	53	50	—	—	—	—	—
Other Operating Expense	-15	1	1	0	—	—	—	—	—
Operating Income	-49	-71	-121	-143	—	—	—	—	—
Interest Expense	8	9	7	3	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	16	12	10	—	—	—	—	—
Net Income Before Taxes	-44	-64	-116	-136	—	—	—	—	—
Income Taxes	3	2	0	0	—	—	—	—	—
Consolidated Net Income	-47	-66	-116	-136	—	—	—	—	—
Net Income From Continuing Operations	-47	-66	-116	-136	—	—	—	—	—
Net Income	-47	-66	-116	-136	—	—	—	—	—
EPS (Recurring)	-1.09	-1.59	-3.07	-4.62	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.09	-1.59	-3.07	-4.62	—	—	—	—	—
EPS (Diluted)	-1.09	-1.59	-3.07	-4.62	—	—	—	—	—
EBITDA	-36	-54	-106	-132	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	5.30	7.63	11.50	34.54	—	—	—	—	—
Gross Margin	90.61	93.35	92.90	94.12	—	—	—	—	—
Operating Margin	-8.07	-15.74	-66.12	-841.18	—	—	—	—	—
Net Margin	-7.74	-14.63	-63.39	-800.00	—	—	—	—	—
Shares Outstanding	43	42	38	29	—	—	—	—	—
Market Capitalization	3,219	3,439	2,104	587	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PYOTT DAVID E I	Director	Sep 15 '26	Option Exercise	0.00	201	0	9,575	Sep 17
LINK WILLIAM J PHD	Director	Sep 15 '26	Option Exercise	0.00	201	0	106,987	Sep 17
LINK WILLIAM J PHD	Director	Sep 15 '26	Sale	78.38	12,500	979,745	94,487	Sep 17
YARNO WENDY L	Director	Sep 15 '26	Option Exercise	0.00	302	0	16,956	Sep 17
Neervannan Seshadri	Chief Operating Officer	Sep 04 '26	Sale	85.00	4,564	387,940	78,532	Sep 09
Lin Elizabeth Yeu	Chief Medical Officer	Sep 04 '26	Sale	87.50	13,953	1,220,885	1,590	Sep 09
Azamian Bobak R.	President/CEO and Board Chair	Sep 04 '26	Sale	90.56	10,000	905,600	827,991	Sep 09
Azamian Bobak R.	President/CEO and Board Chair	Sep 02 '26	Sale	80.06	10,000	800,600	837,991	Sep 03
Lin Elizabeth Yeu	Chief Medical Officer	Sep 02 '26	Sale	80.00	6,977	558,160	4,770	Sep 03
Lin Elizabeth Yeu	Chief Medical Officer	Sep 01 '26	Sale	73.86	4,601	339,830	18,707	Sep 03
Azamian Bobak R.	President/CEO and Board Chair	Jun 17 '26	Sale	61.55	10,000	615,489	847,991	Jun 22
Farrow Jeffrey S	Officer	Jun 16 '26	Sale	60.95	14,396	877,436	56,801	Jun 17
Farrow Jeffrey S	Officer	Jun 15 '26	Option Exercise	0.00	27,881	0	71,197	Jun 17
Goodrich Katherine	Director	Jun 15 '26	Sale	62.08	2,954	183,384	2,233	Jun 17
LINK WILLIAM J PHD	Director	Jun 15 '26	Sale	62.12	12,500	776,495	106,786	Jun 17

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.